Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

Study of REGN2810 in Adults With Cervical Cancer

Complete title: AN OPEN-LABEL, RANDOMIZED, PHASE 3 CLINICAL TRIAL OF REGN2810 VERSUS THERAPY OF INVESTIGATOR'S CHOICE CHEMOTHERAPY IN RECURRENT OR METASTATIC PLATINUM-REFRACTORY CERVICAL CARCINOMA

Research Study Number 20171128
 
Principal Investigator John Liao
 
Phase III

Research Study Description

The primary objective is to compare overall survival (OS) for patients with recurrent or metastatic platinum-refractory cervical cancer treated with either REGN2810 or investigator's choice (IC) chemotherapy.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "LOOK UP TRIAL AT NIH" link above. **

Other eligibility criteria may apply.

Research Study Number 20171128
 
Contact Seattle Cancer Care Alliance Intake Office
 
Telephone 800-804-8824 / 206-606-1024
 

Keywords: Cervical Cancer; Solid Tumors; Uterine Cancer; Urogenital Neoplasms; Genital Neoplasms, Female; Metastatic Solid Tumors

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials